- Letter 140. What to do about borderline hyperglycemia?
- Letter 139. How well do you know your dopamine antagonists?
- Letter 138. Reducing prescribing cascades
- Letter 137. Physical activity is medicine: Prescribe it
- Letter 136. How do YOU respond to Conflicts of Interest?
- Letter 135. Empiric Antibiotic Therapy for Uncomplicated Lower Urinary Tract Infections
- Letter 134. Finding the lowest effective dose for non-opioid analgesics
- Letter 133. Primary hypertension therapy: after thiazide, an ACEI or an ARB?
- Letter 132. Rethinking: Medication Adherence
- Letter 131. Tramadol: Where do we go from here?
- Letter 130. Evidence for statins in people over 70
- Letter 129. Mirtazapine: Update on efficacy, safety, dose response
- Letter 128. Drug Safety Advisories: A need for international coordination
- Letter 127. Audit and Feedback: Personal Prescribing Portrait
- Letter 126. Serious harms with long-term PPI use in older adults
- Letter 125. Can prescribers avoid contributing to opioid use disorder?
- Letter SE. Pill splitting: Making the most of meds in a time of need
- Letter 124. Your views of the Therapeutics Initiative: 2019 Survey
- Letter 123. Biosimilars or Biologics: What’s the difference?
- Letter 122. Twenty-Five Pearls from 25 years (part 2)
- Letter 121. Twenty-Five Pearls from 25 years (part 1)
- Letter 120. Routine VTE prophylaxis: Is there a net health benefit?
- Letter 119. Epinephrine autoinjectors available in Canada
- Letter 118. Trends in utilization of proton pump inhibitors in British Columbia
- Letter 117. Gabapentin and pregabalin: Are high doses justified?
- Letter 116. New drug for cystic fibrosis: Regulatory approval, clinical uncertainty?
- Letter 115. Cannabinoids for Chronic Pain
- Letter 114. Shingrix: A New Vaccine for Shingles
- Letter 113. How well do you know your anticholinergic (antimuscarinic) drugs?
- Letter 112. Antidepressant Withdrawal Syndrome
- Letter 111. Deprescribing Proton Pump Inhibitors
- Letter 110. Stimulants for ADHD in children: Revisited
- Letter 109. Inhaled long acting β2 agonists for COPD
- Letter 108. Drugs to avoid
- Letter 107. EMPA-REG OUTCOME Trial What does it mean?
- Letter 106. Using Best Evidence for the Management of Hypertension
- Letter 105. Is cyclobenzaprine useful for pain?
- Letter 104. Does Medication Review improve health?
- Letter 103. Is the current ‘glucocentric’ approach to management of type 2 diabetes misguided?
- Letter 102. Indacaterol for chronic obstructive pulmonary disease
- Letter 101. Study 329: Why is it so important?
- Letter 100. Questioning the basis of approval for non-insulin glucose lowering drugs
- Letter 99. Comparative effectiveness of proton pump inhibitors
- Letter 98. Does SPRINT change our approach to blood pressure targets?
- Letter 97. Intravenous (IV) iron for severe iron deficiency
- Letter 96. Benefits and harms of drugs for “neuropathic” pain
- Letter 95. Antipsychotics should not be used for non-psychotic depression
- Letter 94. Dual antiplatelet therapy: net health benefit or harm?
- Letter 93. Are claims for newer drugs for overactive bladder warranted?
- Letter 92. The limitations and potential hazards of using surrogate markers
- Letter 91. Is prescribing information from sales representatives balanced?
- Letter 90. Reducing polypharmacy: A logical approach
- Letter 89. Statins proven and associated harms
- Letter 88. Filling the Evidence Gap Pragmatic Randomized Controlled Trials in British Columbia
- Letter 87. High dose versus standard dose statins in stable coronary heart disease
- Letter 86. Your opinions of the Therapeutics Initiative: The 2011 Survey
- Letter 85. Clinical Pearls from Prescrire
- Letter 84. A Systematic Review of the Harms of Bisphosphonates
- Letter 83. A Systematic Review of the Efficacy of Bisphosphonates
- Letter 82. Clinical Hypertension Pearls from The Cochrane Library
- Letter 81. Self-Monitoring of Blood Glucose in Type 2 Diabetes
- Letter 80. Dabigatran for atrial fibrillation Why we can not rely on RE-LY
- Letter 79. Is use of quetiapine for sleep evidence-based?
- Letter 78. Bisphosphonates: Do they prevent or cause bone fractures?
- Letter 77. Do statins have a role in primary prevention? An update
- Letter 76. Are antidepressants safe in pregnancy? A focus on SSRIs
- Letter 75. Gabapentin for pain: New evidence from hidden data
- Letter 74. Increasing use of newer antipsychotics in children: A cause for concern?
- Letter 73. Atomoxetine for ADHD in children and adolescents
- Letter 72. Prescription drug costs: BC versus Canada
- Letter 71. Treatment of elevated blood pressure in the very elderly Less is better
- Letter 70. Clinical Pearls from the most popular Cochrane reviews in 2007
- Letter 69. What is the evidence for using CNS stimulants to treat ADHD in children?
- Letter 68. Glycemic Targets in Type 2 Diabetes
- Letter 67. Evaluating the Media as a source of Drug Therapy Information
- Letter 66. Is newer better? New drugs for treatment of overactive bladder
- Letter 65. Clinical implications of recent key therapeutic trials
- Letter 64. Your opinions of the Therapeutics Letter: The 2006 Survey
- Letter 63. Using Framingham for primary prevention cardiovascular risk assessment
- Letter 62. Mild Hypertension: An approach to using evidence in the decision making process
- Letter 61. What is the Common Drug Review?
- Letter 60. Clinical Pearls from Prescrire
- Letter 59. Increasing Drug Costs: Are we getting good value?
- Letter 58. Benign Prostatic Hypertrophy: An update on drug therapy
- Letter 57. Drugs for Overactive Bladder Symptoms
- Letter 56. Drugs for Alzheimer’s Disease
- Letter 55. Clinical Pearls from The Cochrane Library
- Letter 54. Use of Benzodiazepines in BC Is it consistent with recommendations?
- Letter 53. Rofecoxib (Vioxx®) withdrawal generates uncertainty about “ COX-2s”: Do product monographs adequately inform?
- Letter 52. Antidepressant Medications in Children and Adolescents
- Letter 51. New Drugs VIII
- Letter 50. Can blood pressure be lowered by a change in diet? Evidence from the DASH trials
- Letter 49. Statin’s benefit for secondary prevention confirmed: What is the optimal dosing strategy?
- Letter 48. Do Statins have a Role in Primary Prevention?
- Letter 47. The Answer: Thiazides First-line for Hypertension
- Letter 46. Menopausal Combined Hormone Therapy Update
- Letter 45. Do Single Stereoisomer Drugs Provide Value?
- Letter 44. New Drugs VII
- Letter 43. COX-2 inhibitors update: Do journal publications tell the full story?
- Letter 42. Serious Adverse Event Analysis: Lipid-Lowering Therapy Revisited
- Letter 41. Asymptomatic Bacteriuria in Pregnancy: Rapid answers using the Cochrane Library
- Letter 40. Direct To Consumer Advertising: Finasteride for male pattern hair loss
- Letter 39. Selective COX-2 inhibitors: Are they safer NSAIDs?
- Letter 38. Prevention and Treatment of Influenza A and B
- Letter 37. Antiplatelet Chemoprevention of Occlusive Vascular Events and Death
- Letter 36. New Drugs VI
- Letter 35. Sources of Drug Therapy Information
- Letter 34. New Drugs V
- Letter 33. Treatment of Pain in the Older Patient
- Letter 32. Management of Erectile Dysfunction
- Letter 31. Celecoxib (Celebrex®): Is it a Breakthrough Drug?
- Letter 30. Levels of Evidence for Clinical Decisions: Menopausal Hormone Therapy Revisited
- Letter 29. Leukotriene Antagonists: What is their role in the management of ASTHMA?
- Letter 28. Angiotensin II Receptor Blockers: Their role in hypertension and congestive heart failure
- Letter 27. Review & Update 1998
- Letter 26. New Drugs IV
- Letter 25. Herbal Medicines: An Evidence Based Look
- Letter 24. Lipid Lowering Therapy
- Letter 23. Management of Type 2 Diabetes
- Letter 22. Treatment of Acute Migraine Headaches
- Letter 21. Effective Clinical Tobacco Intervention
- Letter 20. New Drugs III
- Letter 19. Medical Management of Benign Prostatic Hyperplasia
- Letter 18. Management of Anxiety Disorders in Primary Care
- Letter 17. New Drugs 2
- Letter 16. Review and Update 1996
- Letter 15. Evidence Based Drug Therapy: What Do the Numbers Mean?
- Letter 14. Menopausal Hormone Therapy
- Letter 13. New Drugs
- Letter 12. Changing Concepts in the Management of Asthma
- Letter 11. To Sleep or not to Sleep: Here are your Questions
- Letter 10. Dose Titration: Minimize to Maximize
- Letter 9. Review and Update
- Letter 8. Drugs of Choice in the Treatment of Hypertension: Part 2
- Letter 7. Drugs of Choice in the Treatment of Hypertension: Part 1
- Letter 6. Medical Management of Ischemic Heart Disease: The Optimal Use of Nitrates
- Letter 5. Anti-infective Guidelines for Community-Acquired Infections
- Letter 4. Should we be using NSAIDS for the treatment of Osteoarthritis and “Rheumatism”
- Letter 3. Treatment of Gastroesophageal Reflux Disease (GERD)
- Letter 2. Definitive Treatment of Peptic Ulcer Disease by Eradication of Helicobacter Pylori (H. pylori)
- Letter 1. Treatment of Non-Ulcer Dyspepsia in Adults: Common Questions about H2-blockers